Dyne Therapeutics (NASDAQ:DYN) Now Covered by Analysts at Robert W. Baird

Robert W. Baird assumed coverage on shares of Dyne Therapeutics (NASDAQ:DYN) in a report issued on Friday, Marketbeat reports. The brokerage issued an outperform rating and a $46.00 price target on the stock.

A number of other equities analysts have also commented on the company. Stifel Nicolaus increased their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, August 16th. Oppenheimer reissued an “outperform” rating and issued a $55.00 target price on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. JPMorgan Chase & Co. downgraded shares of Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. HC Wainwright reissued a “buy” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. Finally, Piper Sandler restated an “overweight” rating and set a $53.00 target price on shares of Dyne Therapeutics in a research report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $50.42.

Dyne Therapeutics Price Performance

Dyne Therapeutics stock opened at $25.73 on Friday. Dyne Therapeutics has a 1 year low of $11.51 and a 1 year high of $47.45. The firm’s 50 day moving average price is $30.39 and its 200-day moving average price is $35.20. The stock has a market cap of $2.62 billion, a P/E ratio of -7.23 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, equities analysts expect that Dyne Therapeutics will post -3.45 EPS for the current year.

Insider Buying and Selling at Dyne Therapeutics

In related news, Director Carlo Incerti sold 16,500 shares of Dyne Therapeutics stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $28.73, for a total transaction of $474,045.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Oxana Beskrovnaya sold 2,334 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total transaction of $65,632.08. Following the completion of the sale, the insider now directly owns 201,685 shares of the company’s stock, valued at approximately $5,671,382.20. This trade represents a 1.14 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 180,046 shares of company stock worth $6,300,265 over the last 90 days. Company insiders own 20.77% of the company’s stock.

Institutional Trading of Dyne Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC raised its holdings in shares of Dyne Therapeutics by 904.1% in the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after acquiring an additional 669 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Dyne Therapeutics in the 3rd quarter valued at about $34,000. Point72 DIFC Ltd purchased a new stake in shares of Dyne Therapeutics in the 3rd quarter worth approximately $36,000. US Bancorp DE lifted its position in shares of Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the period. Finally, Values First Advisors Inc. purchased a new position in Dyne Therapeutics during the third quarter valued at approximately $62,000. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.